该股主要指标及行业内排名如下： 美好医疗融资融券信息显示，融资方面，当日融资买入5743.01万元，融资偿还3516.2万元，融资净买入 2226.81万元。融券方面，融券卖出7600.0股，融券偿还6000.0股，融券余量5.9万股，融券余额193.81万 元。融资融券余额2.98亿元。 近5日融资融券数据一览见下表： 证券之星消息，截至2026年2月24日收盘，美好医疗(301363)报收于32.86元，下跌5.79%，换手率 4.54%，成交量16.93万手，成交额5.55亿元。 2月24日的资金流向数据方面，主力资金净流出4036.56万元，占总成交额7.28%，游资资金净流入 2331.2万元，占总成交额4.2%，散户资金净流入1705.35万元，占总成交额3.08%。 近5日资金流向一览见下表： 美好医疗2025年三季报显示，前三季度公司主营收入11.94亿元，同比上升3.28%；归母净利润2.08亿 元，同比下降19.25%；扣非净利润2.03亿元，同比下降17.85%；其中2025年第三季度，公司单季度主营 收入4.62亿元，同比上升2.56%；单季度归母净利润9390.02万元，同比上升5. ...

资料显示，东富龙科技集团股份有限公司位于上海市闵行区都会路1509号，成立日期1993年12月25日， 上市日期2011年2月1日，公司主营业务涉及医用冻干机及冻干系统的研发、设计、生产、销售和服务。 主营业务收入构成为：制剂事业部44.92%，生物工艺事业部29.83%，工程事业部9.19%，食品事业部 9.16%，售后服务与配件6.81%，其他(补充)0.09%。 截至9月30日，东富龙股东户数3.14万，较上期减少2.14%；人均流通股17910股，较上期增加2.19%。 2025年1月-9月，东富龙实现营业收入37.04亿元，同比增长6.14%；归母净利润1.32亿元，同比减少 13.86%。 2月24日，东富龙涨1.08%，成交额1.40亿元。两融数据显示，当日东富龙获融资买入额1297.62万元， 融资偿还1176.89万元，融资净买入120.72万元。截至2月24日，东富龙融资融券余额合计2.51亿元。 融资方面，东富龙当日融资买入1297.62万元。当前融资余额2.50亿元，占流通市值的1.93%，融资余额 低于近一年20%分位水平，处于低位。 融券方面，东富龙2月24日融券偿还1800.00 ...

Alphatec Holdings, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance Drivers Achieved 25% annual revenue growth by leveraging a 100% spine-focused strategy in a disrupted market, prioritizing proceduralization over individual products. Expanded the lateral addressable market by converting surgeons from traditional posterior approaches to the proprietary PTP (Prone Transpsoas) technique. Utilized the EOS Edge imaging system as a 'gold standard' entry point to gain access to previously u ...

精锋医疗、北芯生命等医疗器械股接连上市，涨势颇佳；脑机接口引发一二级市场集体狂欢，博睿康、强脑科技冲刺IPO，上海另一家侵入式脑机创业公司 估值也超过45亿元。 如今，超百家医疗公司在港股排队，IPO政策即将收紧的风声广为流传，甚至有行业人士认为"新股破发30%会成为常态"。那么，2026年医疗公司上市的窗 口和机遇究竟如何？拟IPO公司正如何聪明地应对行情风险？ 去年创新药板块创造了许多财富神话：6000倍打新"认购王"、百余家公司年内股价翻倍等。2026年，更多基石和早期投资人会相继解禁，情绪与浮华褪去， 还得靠硬实力撑住长期市值。BD交易的规模和结构，仍是市场判断药企和新药分子质地的关键。 历经一年洗礼，资本市场对于创新药License-out（对外授权）的反应愈发理性，"BD拉不动股价"也时有发生。2026年MNC对中国新药资产的热情不减，除 了已然拥挤的肿瘤赛道，哪些新方向正成为大药企竞逐的热点？ 新药BD授权的玩家中，AI native的生物医药公司已然不容小觑。近一个多月，英矽智能、华深智药等频获BD交易，国内某AI制药明星创业公司估值拉至30 亿美金。新药老炮儿们如何看待"AI科学家"在药物开 ...

大健康产业是关乎民生福祉、承载经济转型希望的新兴产业,也是聊城市重点打造的4条标志性产业链之 一。2025年以来,全市以《聊城市大健康产业发展规划(2024—2028年)》为蓝图,聚焦医药制品、健康食 品、医疗器械三大领域,将品牌建设作为核心引擎,着力推动产业链从"单点突破"向"集群协同"升级,从"传 统制造"向"高端智造"跨越。 目前,全市大健康产业链规上企业达52家,2025年实现产值114.5亿元,同比增长9.8%；营业收入102.7亿元, 同比增长6.2%；利润总额20.3亿元,同比增长13.2%,呈现出稳健向上的发展态势。特别值得一提的是,东 阿阿胶（000423）、冠县灵芝产业集群先后入选省级医养健康特色产业集群；全市大健康产业集群入选 省"十强产业"雁阵形产业集群储备库；聊城市参与联合申报的沿黄中医药产业集群入选省"十强产业"支 柱型雁阵集群,品牌赋能的叠加效应持续释放。 聊城市卫生健康委员会举行"品牌赋能大健康产业高质量融合发展"主题发布会,聊城市计划生育协会副 会长、大健康产业链专班办公室主任纪浩晴介绍了聊城市大健康产业链发展的有关情况。 陶春燕 聊城报道 构建品牌矩阵 筑牢产业发展"金招牌 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 赛诺医疗科学技术股份有限公司（以下简称"赛诺医疗"或"公司"） 控股子公司赛诺神畅医疗科技有限 公司（以下简称"赛诺神畅"）于2024年向欧盟公告机构递交了公司Ghunter颅内取栓支架按照欧盟医疗 器械法规Medical Devices Regulation（EU）2017/745（简称"MDR"）注册认证的申报资料。赛诺神畅于 近日收到欧盟公告机构通知，Ghunter颅内取栓支架获得按照欧盟MDR法规签发的欧盟CE MDR认证。 现将相关情况公告如下： 一、注册证内容 证书名称：EU Quality Management System Certificate、 证书编号：2291466TD01, 2291466CE01 EU Technical Documentation Assessment Certificate 二、医疗器械基本情况 本次获得欧盟公告机构批准的Ghunter颅内取栓支架，是赛诺神畅自主研发的一款急性缺血类产品。全 显影设计，增加手术过 ...

Financial Performance - For the full year 2025, the company reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share of $3.98, growing 30.8% [5][24] - In Q4 2025, revenue totaled $826.4 million, growing 25.7% compared to Q4 2024, with non-GAAP EPS at $1.28, a growth of 52.1% [6][25] - The base business revenue for Q4 was $726.7 million, growing 10.6% year-over-year, with a consolidated Adjusted EBITDA margin of 33.9% [6][25] Business Line Performance - The U.S. spine business grew 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [7][28] - Enabling Technologies revenue reached $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][27] - The trauma business delivered approximately 27% growth in Q4, supported by the uptake of the legacy trauma line and new product launches [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, growing 19% [27][28] - The international spine business faced challenges earlier in the year but showed incremental improvement, culminating in a record sales quarter in Q4 2025 [29][28] - Growth in international markets was led by enabling technologies and the spine business, particularly in the UK, Australia, Germany, Brazil, Mexico, and Poland [28] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base, with a focus on innovation in product development [15][18] - The integration of Nevro is expected to enhance the company's portfolio, allowing entry into adjacent markets while driving differentiation in legacy businesses [18][17] - The company remains competitive in the evolving market landscape, emphasizing the unique capabilities of its ExcelsiusGPS platform [12][14] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and an expanded sales force as key drivers [70] - The company anticipates continued margin expansion, with a target of achieving a gross profit margin in the range of 69%-70% for 2026 [32][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates as the year progresses [81][80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a new share repurchase program of $500 million announced [38][39] - Full-year 2025 SG&A expenses were $1.178 billion, or 40% of sales, with expectations for 2026 to be in the range of 38%-39% [36][43] - The company achieved $200 million in synergies from the NuVasive acquisition, exceeding initial targets [41][42] Q&A Session Summary Question: Can you bridge the growth expectations for the base business from 2025 to 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [49][50] Question: How did the company perform in terms of market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market, with evidence from consistent growth rates [56][57] Question: What contributed to the recovery in enabling technology performance? - Management indicated that the fourth quarter saw a closure of delayed pipeline deals, contributing to the improved performance [62][63] Question: How sustainable is the U.S. spine growth, especially with new competition? - Management expressed confidence in the durability of U.S. spine growth, emphasizing ongoing product launches and competitive strategies [70][71] Question: What are the challenges and growth prospects for the international business? - Management highlighted the potential for 12%-15% growth in international markets, focusing on deeper penetration rather than expansion into new countries [81][80]

Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share of $3.98, up 30.8% [6][24] - In Q4 2025, revenue reached $826.4 million, growing 25.7% compared to Q4 2024, with non-GAAP EPS at $1.28, a 52.1% increase [7][25] - The adjusted gross margin for Q4 was 69.2%, compared to 67.1% in the prior year quarter, driven by favorable sales mix and synergy execution [30][31] Business Line Performance - The U.S. spine business grew 10% in Q4 2025 compared to the prior year quarter, continuing a trend of above-market growth [8][28] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [12][27] - The trauma business delivered approximately 27% growth in Q4, supported by the legacy trauma line and new product launches [16][17] Market Performance - U.S. revenue in Q4 2025 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, growing 19% [27][28] - The international spine business faced challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [29][83] Company Strategy and Industry Competition - The company aims to expand its core spine business while growing other segments, positioning itself as a procedure-enabling medtech platform integrating imaging, navigation, robotics, and implants [19][20] - The competitive landscape is evolving, with new robotic navigation systems entering the market, but the company believes its ExcelsiusGPS system remains a strong option for customers [13][73] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in sustained growth momentum, particularly in the U.S. spine business, and anticipates continued above-market growth in 2026 [9][71] - The company expects to achieve a full-year adjusted gross margin of 69%-70% in 2026, reflecting ongoing improvements in manufacturing initiatives [32][43] Other Important Information - The company repurchased approximately 4.3 million shares for $300.5 million during 2025, with a new share repurchase program of $500 million announced [39] - Full-year 2025 SG&A expenses were $1.178 billion, or 40% of sales, with expectations for 2026 to be in the range of 38%-39% [36] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [49][50] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [58] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [62][63] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [71][72] Question: What are the headwinds in the international market? - Management identified challenges in the APAC region, particularly Japan, but believes there are ample opportunities for growth in existing markets [82][83]

Merit Medical Systems (NasdaqGS:MMSI) Q4 2025 Earnings call February 24, 2026 04:30 PM ET Company ParticipantsAidan Lahey - Equity Research AssociateBrian G. Lloyd - Chief Legal Officer and Corporate SecretaryMartha Aronson - President and CEORaul Parra - CFO and TreasurerConference Call ParticipantsDavid Rescott - Director and Senior Research AnalystJason Bednar - Managing Director and Senior Research AnalystJayson Bedford - Managing Director and Senior AnalystJim Sidoti - Senior Equity AnalystJohn Young - ...

Financial Performance - For the full year 2025, Globus Medical reported revenue of $2.939 billion, representing a growth of 16.7% year-over-year, and non-GAAP earnings per share (EPS) of $3.98, up 30.8% [4][22] - In Q4 2025, revenue reached $826.4 million, a 25.7% increase compared to Q4 2024, with non-GAAP EPS of $1.28, growing 52.1% year-over-year [5][23] - The base business revenue for Q4 was $726.7 million, reflecting a 10.6% growth compared to the same quarter last year [5][25] - Adjusted EBITDA margin for Q4 was 35.7%, while the full year margin was 33.4% [6][24] Business Line Performance - The U.S. spine business grew by 10% in Q4 compared to the prior year quarter, continuing a trend of above-market growth [6][27] - Enabling Technologies revenue was $55.6 million in Q4, growing 18.5% year-over-year, driven by increased sales of EGPS systems [11][26] - The trauma business experienced approximately 27% growth in Q4, supported by the legacy trauma line and precise limb lengthening products [15][16] Market Performance - U.S. revenue in Q4 was $665.3 million, growing 27.5% year-over-year, while international revenue was $161.1 million, reflecting a 19% increase [26][27] - The international spine business faced supply chain challenges earlier in the year but showed improvement, culminating in record sales in Q4 2025 [28][80] Company Strategy and Industry Competition - The company aims to penetrate and launch new programs while fostering utilization and service excellence across its install base [14] - Globus Medical is focused on expanding its core spine business while also growing adjacent markets through innovation and product development [18][19] - The company views competition in the enabling technology space as evolving but believes its ExcelsiusGPS system remains a strong offering [12][69] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the sustainability of U.S. spine growth, citing product launches and a robust sales force as key drivers [68] - The company anticipates continued margin expansion and has set a long-term goal for mid-seventies adjusted gross profit percentage [30][43] - Management acknowledged the challenges faced in international markets but remains optimistic about returning to double-digit growth rates [80] Other Important Information - The company repurchased approximately 4.3 million shares during 2025, with a remaining authorization of $390 million under its share repurchase program [37][38] - Research and development expenses for Q4 were $36.2 million, or 4.4% of sales, reflecting a decrease from the prior year [30][32] Q&A Session Summary Question: Can you bridge the growth expectations for the base business into 2026? - Management noted that 2025 was a tale of two halves, with significant growth in the latter half driven by product launches and sales force expansion [47][48] Question: How do you view market share and the strength of the spine market? - Management believes the U.S. spine business is growing above market and views the overall spine market as relatively healthy [54] Question: What changed in the enabling technology environment? - Management indicated that enabling technology performance was lumpy throughout the year, with a strong Q4 driven by closing delayed pipeline deals [59][60] Question: How sustainable is the U.S. spine growth? - Management sees the growth as durable, supported by ongoing product launches and competitive rep conversions [68][69] Question: What are the headwinds in the international market? - Management highlighted that the international business can grow 12%-15% long-term, with a focus on deepening existing markets rather than expanding into new ones [80]